MTOR and cardiomyopathy: Collectively, taking advantage of the overexpression of FoxO3 in H9c2 cardiomyocytes and the heart, FoxO3 is found to protect against DOX cardiotoxicity by activating autophagy, inhibiting intracellular ROS and mTOR signalling, thus revealing the therapeutic potential of FoxO3 as a target in DOX cardiomyopathy clinically.